dendritic cell vaccination + bevacizumab

Dendritic cell vaccination + bevacizumab is a combination therapy that leverages two distinct mechanisms to target cancer. This approach combines immunotherapy (dendritic cell vaccination) with anti-angiogenesis therapy (bevacizumab). Dendritic cell vaccination involves using autologous dendritic cells that are generated after leukapheresis and loaded with tumor antigens. These cells are then administered back to the patient to stimulate an immune response against the tumor. Dendritic cells function as antigen-presenting cells that activate T cells, promoting antitumor immunity[1][3][4]. Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that inhibits vascular endothelial growth factor (VEGF) by preventing its binding to VEGF receptors (VEGFR-1 and VEGFR-2). This inhibition prevents cell proliferation and new blood vessel formation in tumor angiogenesis, potentially inhibiting tumor growth and metastatic disease progression[6][8][9]. Research suggests that bevacizumab may enhance the efficacy of dendritic cell vaccination by improving tumor infiltration of mature dendritic cells and effector T cells, as demonstrated in triple-negative breast cancer patients[2]. The combination aims to overcome the limitations of each therapy used alone and potentially provide synergistic effects in cancer treatment. ## Clinical Applications This combination has been studied in various cancer types, including: **Malignant Gliomas**: Studies have compared dendritic cell vaccination with the bevacizumab plus irinotecan protocol for recurrent malignant gliomas. A survival gain analysis showed no significant difference between the two approaches in terms of survival gain, suggesting that dendritic cell vaccination might be an alternative to bevacizumab and irinotecan for these patients[1][3]. **Triple-Negative Breast Cancer**: Research has shown that a single dose of bevacizumab can reduce the density of angiopoietin-2-positive vessels while improving the infiltration of CD4+ T cells, CD8+ T cells, and mature dendritic cells in patients with primary triple-negative breast cancer. This provides a rationale for including bevacizumab during neoadjuvant treatment to enhance the efficacy of immune checkpoint blockers in this disease[2]. The combination therapy represents a promising approach that may offer benefits over either treatment alone, particularly in cancers that have shown resistance to standard therapies.